drugset / Trial / NCT01732094

Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders

NCT01732094

Phase 2 Completed 57 enrolled University Hospital Brussels
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the present study is to examine the level of ovarian response and the pregnancy rates among poor ovarian responders treated with a novel treatment protocol with 150μg corifollitropin alfa followed by 300IU hMG in a long GnRH agonist protocol.

Timeline

Start
2012-07
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Corifollitropin alfa Protein / enzyme biologic 150 ug
Subject Menopur Protein / enzyme biologic 300 iu
Background Triptorelin Other / unclassified 0.1 mg